Sentence examples for multiple sclerosis therapy from inspiring English sources

Biogen Idec and Elan fell in response to safety concerns related to the multiple sclerosis therapy Tysabri.

On Wednesday, Biogen Idec said it would pay Acorda Therapeutics up to $510 million for the rights to market Fampridine SR, an experimental oral multiple sclerosis therapy, overseas.

Biogen Idec was struggling after additional safety concerns arose regarding its multiple sclerosis therapy Tysabri, with two new cases of a rare brain disease linked to the drug.

S1P-signalling has recently received a great deal of attention in multiple sclerosis therapy due to the promise of FTY720 [2-amino-2-[2- 4-octylphenyl [2-amino-2-[2- 4-octylphenyl [2-amino-2-[2- 4-octylphenyl [2-amino-2-[2- 4-octylphenyl [2-amino-2-[2- 4-octylphenyl [2-amino-2-[2- 4-octylphenyl

Serono, of Geneva, wants to gain Food and Drug Administration approval of Rebif, which controls about a third of the market outside the United States, to break Biogen's hold on the $1 billion American market for multiple sclerosis therapies.

Future multiple sclerosis therapies arising from this research may offer better suppression of disease activity, but may be associated with potentially severe side-effects in some patients that may be difficult to manage.

Both locations were near some of the Romneys' grandchildren and the La Jolla location was near where she rides horses and was well-situated for her multiple sclerosis therapies and for recovering from her cancer treatments.

The La Jolla home proved beneficial in location and climate for Ann Romney's multiple sclerosis therapies and for recovering from her late 2008 diagnosis of mammary ductal carcinoma in situ and subsequent lumpectomy.

The unique accessibility and structure-function correlations provided by the afferent visual system in multiple sclerosis, combined with additional understanding provided by electrophysiology, make vision a useful model system to test new multiple sclerosis therapies.

43– 46 Taken together, modes of action of FTY720 render the drug unique when compared with other multiple sclerosis therapies, particularly in terms of its potential neuroprotective and neuroregenerative effect.

Tysabri, approved in November, is the most expensive multiple-sclerosis therapy on the market, costing about $23,000 a year.